A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 29 Aug 2017
At a glance
- Drugs ALT 801 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Altor BioScience Corporation
- 10 Jun 2017 Biomarkers information updated
- 13 Jul 2016 Status changed from active, no longer recruiting to discontinued.
- 08 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016, according to ClinicalTrials.gov record.